Table 4

BRCA mutation prevalence in families with ovarian cancer (OC) only (group 2a), both breast cancer (BC) and OC (group 2b), and male breast cancer (mBC) (group 3)

Families with pathogenic mutation
FamiliesBRCA1/2BRCA1BRCA2
GroupFamilial cancer history (including proband)N% of totalnPrev (%)95% CI (%)nPrev (%)95% CI (%)nPrev (%)95% CI (%)
Group 2a: OC only2 OC
(no BC, mBC)
1940.97940.734.1 to 47.85025.820.1 to 32.42914.910.6 to 20.6
≥3 OC
(no BC, mBC)
660.33045.534.0 to 57.42740.929.9 to 53.057.63.3 to 16.5
Total2601.210941.936.1 to 48.07729.624.4 to 35.43413.19.5 to 17.7
Group 2b: OC and female BC,
but no mBC
1 BC51+OC
(no mBC)
1180.62420.314.1 to 28.51714.49.2 to 21.975.92.9 to 11.7
1 BC50−OC
(no mBC)
1450.77149.041.0 to 57.05638.631.1 to 46.71510.36.4 to 16.4
≥2 BCOC
(no mBC)
110.1763.635.4 to 84.8763.635.4 to 84.800.00.0 to 25.9
≥2 BCOC+≥1 BC/OC (no mBC)14826.979653.751.2 to 56.264143.340.8 to 45.816010.89.3 to 12.5
1 BC51++1 OC
(no mBC, BCOC)
3331.66419.215.3 to 23.83911.78.7 to 15.6267.85.4 to 11.2
1 BC50−+1 OC (no mBC, BCOC)6453.020331.528.0 to 35.215524.020.9 to 27.5487.45.7 to 9.7
1 BC+≥2 OC
(no mBC, BCOC)
2481.211345.639.5 to 51.810040.334.4 to 46.5135.23.1 to 8.8
≥2 BC+≥1 OC (no mBC, BCOC)20909.883339.937.8 to 42.060929.127.2 to 31.123111.19.8 to 12.5
Total507223.7211141.640.3 to 43.0162432.030.7 to 33.35009.99.1 to 10.7
Group 3: mBC1 mBC+1 BC51+
(no OC)
970.51616.510.4 to 25.133.11.1 to 8.71313.48.0 to 21.6
1 mBC+1 BC50−
(no OC)
990.52323.216.0 to 32.555.12.2 to 11.31818.211.8 to 26.9
1 mBC+≥2 BC
(no OC)
3311.512838.733.6 to 44.0298.86.2 to 12.310030.225.5 to 35.4
≥2 mBC+≥1 BC
(no OC)
230.11565.244.9 to 81.214.30.8 to 21.01565.244.9 to 81.2
1 mBC+≥1 OC
(no BC)
150.1853.330.1 to 75.2426.710.9 to 52.0426.710.9 to 52.0
≥1 mBC+≥1 BC
+≥1 OC
770.44051.941.0 to 62.71823.415.3 to 34.02329.920.8 to 40.8
Total6423.023035.832.2 to 39.6609.37.3 to 11.817326.923.7 to 30.5
  • Prev, prevalence.